Mechanism-Based Approach to the Economic Evaluation of Pharmaceuticals

List of Tables

Table 1: Advantages and Disadvantages of population pharmacokinetics modelling .................................................. 6

Table 2: Parameter estimates for the final Glicaprevir model [71]. IIV = inter-individual variability, SEE = Standard Error of Estimate, % RSE = Relative Standard Error) ........................................................................ 25

Table 3: Parameter estimates for the final Pibrentasvir model [71]. IIV = inter-individual variability, SEE = Standard Error of Estimate, % RSE = Relative Standard Error) ........................................................................ 26

Table 4: Average ages of Phase 2 clinical studies made in FDA submission report for Mavyret™ [71], accessed in clinical trial website [74] .......................................................................................................................... 29

Table 5: Average ages of Phase 3 clinical studies made in FDA submission report for Mavyret™ [71], accessed in clinical trial website [74] .......................................................................................................................... 30

Table 6: The table display the calculated values from AUC (mg.h/L) and Cmax (mg/L) of both drugs (Glicaprevir and Pibrentasvir) when no covariate is used in the model.................................................................................. 38

Table 7: The table display the calculated values from AUC (mg.h/L) and Cmax (mg/L) of both drugs (Glicaprevir and Pibrentasvir) when a model with a patient of mild renal impairment is used................................................... 41

Table 8: The table display the calculated values from AUC (mg.h/L) and Cmax (mg/L) of both drugs (Glicaprevir and Pibrentasvir) when a model with a patient of mild renal impairment and cirrhosis is used ............ 43

Table 9: The table display the calculated values from AUC (mg.h/L) and Cmax (mg/L) of both drugs (Glicaprevir and Pibrentasvir) when a model with patients of moderate + severe renal impairment is used........................................ 44

Table 10: The table display the calculated values from AUC (mg.h/L) and Cmax (mg/L) of both drugs (Glicaprevir and Pibrentasvir) when a model with a patient of mild renal impairment and cirrhosis is used .................. 46

Table 11: The table display the calculated values from AUC (mg.h/L) and Cmax (mg/L) of both drugs (Glicaprevir and Pibrentasvir) when a model with patients end stage impairment is used ........................................ 47

Table 12: The table display the calculated values from AUC (mg.h/L) and Cmax (mg/L) of both drugs (Glicaprevir and Pibrentasvir) when a model with patients end stage impairment and cirrhosis is used .... 49